Could a common steroid shorten hospital stays for severe pancreatitis?

NCT ID NCT05160506

Recruiting now Disease control Sponsor: Beth Israel Deaconess Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a short course of the steroid hydrocortisone can reduce inflammation and improve outcomes for people with severe pancreatitis. Researchers will give the drug or a placebo to 86 ICU patients and track their organ failure scores and hospital stay length. The goal is to see if this simple anti-inflammatory approach can prevent the disease from getting worse.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Hydrocortisone (a steroid anti-inflammatory drug)
What this could lead to: If it works, this could provide a simple, short-term treatment to reduce complications and shorten hospital stays for severe pancreatitis.
What could go wrong: This is a small, early-phase trial (86 people) testing a common drug, so results may not be definitive. Steroids also carry risks like infection or blood sugar changes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CORTICOSTEROID are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute pancreatitis pancreatitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CORTICOSTEROID HYDROCORTISONE PANCREATITIS PANCREATITIS, ACUTE

Contacts and locations

Locations

Beth Israel Deaconess Medical Center
RECRUITING

Boston, Massachusetts, 02215, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.